A purified form of tamoxifen (see designer estrogens). Appears to be less estrogenic than tamoxifen in the endometrium, and may be less likely to cause uterine cancer. Brand name Evista.
a selective estrogen receptor modulator (SERM) that slows bone loss. Under the brand name Evista, it has been approved by the FDA for use in the prevention and treatment of osteoporosis.
A drug recently approved for the prevention of osteoporosis that prevents bone loss. It is from a new class of drugs called Selective Estrogen Receptor Modulators (SERMs).
Brand name, Evista. Drug used to prevent and treat osteoporosis. Raloxifene is also being studied to determine whether it can safely and effectively prevent breast cancer in women at high risk for the disease since it is chemically similar to the drug tamoxifen.
a selective estrogen receptor modulator (SERM) that is an antiresorptive agent in bone; it is marketed by Eli Lilly under the name Evista
An approved osteoporosis medication that is undergoing trials to determine whether it can prevent breast cancer in women at high risk for the disease. Raloxifene is chemically similar to the drug tamoxifen.
Hormone treatment for osteoporosis which may protect against breast cancer in the same manner as tamoxifen in low risk postmenopausal women, but without the complication of uterine cancer. Currently in clinical trials
a SERM drug, available as Evista®, used to prevent osteoporosis
A drug that belongs to the family of drugs called selective estrogen receptor modulators (SERMs) and is used in the prevention of osteoporosis in postmenopausal women. Raloxifene is also being studied as a cancer prevention drug.
Raloxifene is an oral selective estrogen receptor modulator which is used in the prevention of osteoporosis in postmenopausal women. It was announced on April 17, 2006, that raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in certain high risk groups of females, http://www.cancer.gov/clinicaltrials/digestpage/STAR/page2 though with a reduced risk of thromboembolic events and cataracts in patients taking raloxifene versus those taking tamoxifen. It has not been approved by the FDA for this use, and there has been criticism in the mainstream oncology press of the way that the information was released.